What TV doesn't, print can't; we deliver.
What TV doesn't, print can't; we deliver.
Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and developer of vaccines for infectious diseases, on Wednesday announced its rotavirus oral vaccine ROTAVAC® has been introduced by Nigeria to immunize its children
Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and developer of vaccines for infectious diseases, on Wednesday announced its rotavirus oral vaccine ROTAVAC® has been introduced by Nigeria to immunize its children from the life-threatening diarrhoeal disease that affects millions of children worldwide.
Nigeria currently accounts for 14 per cent of all childhood rotavirus deaths globally, making it the country with the second-highest number of rotavirus deaths in the world. Rotavirus infection causes about 50,000 child fatalities under the age of five each year in Nigeria.
Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech, said, “Decades of research and product development have resulted in ROTAVAC®. This vaccine is now available in several countries across Asia, Africa, Latin America, and the Middle East. We are proud to state that novel vaccines from India are saving lives worldwide.”
“We are committed to supporting, and reducing the infectious disease burden among children in the developing world, and to ensure nations like Nigeria in the African continent, have access to cost-effective world-class interventions for infants and vulnerable populations. ROTAVAC® is safe and effective at preventing diarrhoeal disease caused by the Rotavirus.”
Ella added, “Bharat Biotech will continue to play its role in researching, developing, and manufacturing novel vaccines, to lower the morbidity and mortality from infectious diseases and contribute towards the achievement of universal vaccine access.”
Rotavirus is one of the leading causes of diarrhoeal disease in the world and is responsible for over 40 per cent of diarrhoea in children. It accounts for about 215,000 of the 525,000-under-5 mortality worldwide each year that are attributed to diarrhoeal diseases, making it the most common cause of severe diarrhoea.
ROTAVAC® received WHO-Prequalification in January 2018. Bharat Biotech developed the first generation, rotavirus vaccine, Rotavac under a Public-Private Partnership with the Department of Biotechnology, Government of India and 16 other international partners, making it the largest ever social innovation project for public health.
Bharat Biotech is a global leader in rotavirus vaccines, with one of the largest manufacturing capacities.
